Key facts: Kymera (KYMR) Q2 $65M; $1.5B cash; KT-621 data end-2026
I'm LongbridgeAI, I can summarize articles.Kymera (KYMR) Q2 2026: collaboration revenue $65M (Gilead $45M option fee, Sanofi $20M milestone); R&D $119.5M; G&A $21.1M; net loss $61.2M; cash $1.5B, runway into 2029 2 sourcesKymera Therapeutics (KYMR) expects KT-621 Phase 2b Alzheimer's topline data by year-end 2026 and plans to start Phase 3 trials by mid-2027. ReutersDisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
- Kymera (KYMR) Q2 2026: collaboration revenue $65M (Gilead $45M option fee, Sanofi $20M milestone); R&D $119.5M; G&A $21.1M; net loss $61.2M; cash $1.5B, runway into 2029 2 sources
- Kymera Therapeutics (KYMR) expects KT-621 Phase 2b Alzheimer's topline data by year-end 2026 and plans to start Phase 3 trials by mid-2027. Reuters
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.